[{"id":"b7618037-1369-4803-9a4d-36cc465a98d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159906","created_at":"2025-09-13T08:44:39.729Z","updated_at":"2025-09-13T08:44:39.729Z","phase":"Phase 1/2","brief_title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT07159906","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • prednisone • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/08/2025","start_date":" 09/08/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-09-08"},{"id":"893adf5f-401b-45ed-b55a-95592085576f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874194","created_at":"2021-05-05T11:52:46.095Z","updated_at":"2024-07-02T16:35:02.356Z","phase":"Phase 1/2","brief_title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","source_id_and_acronym":"NCT04874194","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RUNX1","pipe":" | ","alterations":" RUNX1 mutation","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-21"},{"id":"a40edb33-4956-4fcb-af35-db7081c0b606","acronym":"","url":"https://clinicaltrials.gov/study/NCT06328179","created_at":"2024-03-25T17:36:14.935Z","updated_at":"2024-07-02T16:35:12.972Z","phase":"","brief_title":"Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.","source_id_and_acronym":"NCT06328179","lead_sponsor":"Huai'an First People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-03-25"},{"id":"efb2f664-87fd-4928-b92b-66faede8e3da","acronym":"HQP1351CC203","url":"https://clinicaltrials.gov/study/NCT04126681","created_at":"2021-01-18T20:09:35.310Z","updated_at":"2024-07-02T16:35:51.472Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT04126681 - HQP1351CC203","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Nailike (olverembatinib) • Synribo (omacetaxine mepesuccinate) • hydroxyurea"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-04-04"},{"id":"65fd0f21-bb1f-4a94-8034-695d863b7486","acronym":"","url":"https://clinicaltrials.gov/study/NCT05513131","created_at":"2022-08-24T21:07:32.097Z","updated_at":"2024-07-02T16:36:04.923Z","phase":"Phase 2","brief_title":"Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML","source_id_and_acronym":"NCT05513131","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2022-08-24"},{"id":"3dc09b40-82a5-425d-b8e9-5b1b7d8b100e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00462943","created_at":"2021-12-28T22:53:39.815Z","updated_at":"2024-07-02T16:36:19.138Z","phase":"Phase 2","brief_title":"Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML","source_id_and_acronym":"NCT00462943","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 03/07/2007","start_date":" 03/07/2007","primary_txt":" Primary completion: 08/04/2009","primary_completion_date":" 08/04/2009","study_txt":" Completion: 06/27/2013","study_completion_date":" 06/27/2013","last_update_posted":"2021-12-28"},{"id":"e42a85e3-8a8f-4ba5-b42b-6faaef554669","acronym":"","url":"https://clinicaltrials.gov/study/NCT00375219","created_at":"2021-11-11T18:45:16.493Z","updated_at":"2024-07-02T16:36:20.742Z","phase":"Phase 2","brief_title":"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation","source_id_and_acronym":"NCT00375219","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Synribo (omacetaxine mepesuccinate)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 09/20/2006","start_date":" 09/20/2006","primary_txt":" Primary completion: 03/23/2010","primary_completion_date":" 03/23/2010","study_txt":" Completion: 06/28/2013","study_completion_date":" 06/28/2013","last_update_posted":"2021-11-15"},{"id":"df226a48-91d3-42e6-9f95-b3bd2cc6de70","acronym":"ALIVE","url":"https://clinicaltrials.gov/study/NCT04716114","created_at":"2021-03-26T11:56:14.334Z","updated_at":"2024-07-02T16:36:21.704Z","phase":"Phase 3","brief_title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","source_id_and_acronym":"NCT04716114 - ALIVE","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • fludarabine IV • Synribo (omacetaxine mepesuccinate) • aclarubicin • ruserontinib (SKLB-1028)"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-11-02"},{"id":"bf75e380-cf06-45ab-9526-c6dc47a6700e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505995","created_at":"2021-01-18T21:36:19.252Z","updated_at":"2024-07-02T16:36:42.207Z","phase":"","brief_title":"Azacitidine and Homoharringtonine in JMML","source_id_and_acronym":"NCT04505995","lead_sponsor":"Fourth Military Medical University","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2020-08-10"}]